Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Kantarjian, Hagop M., Shah, Neil P., Cortes, Jorge E., Baccarani, Michele, Agarwal, Mohan B., Undurraga, María Soledad, Wang, Jianxiang, Kassack Ipiña, Juan Julio, Kim, Dong-Wook, Ogura, Michinori, Pavlovsky, Carolina, Junghanss, Christian, Milone, Jorge H., Nicolini, Franck E., Robak, Tadeusz, Van Droogenbroeck, Jan, Vellenga, Edo, Bradley-Garelik, M. Brigid, Zhu, Chao, Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916556/
https://ncbi.nlm.nih.gov/pubmed/22160483
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-376087
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares